Revenue distribution by sectors:

• Pharmaceutical products: approx. 70%
• Dietary supplements: approx. 20%
• Cosmetic products: approx. 10%

TOP 3 markets and their percentage shares:

• Germany: approx. 50%
• Austria: approx. 15%
• Switzerland: approx. 10%

Dermapharm Holding SE generates the majority of its revenue from the pharmaceutical products sector, reflecting the company's core competence. The German market is the most significant individual market for the company, followed by Austria and Switzerland. These markets benefit from a strong brand presence and a well-established distribution network.

Production Sites: Germany, Spain, Italy

Dermapharm Holding SE mainly produces its products in Germany, with several production facilities in the country. In addition, the company has also established production capacities in Spain and Italy.

This geographical diversification enables Dermapharm to efficiently respond to different market requirements and optimize their supply chains. The strategic placement of the production sites also supports the rapid market introduction of new products in various European markets.

Revenue Growth: Estimated 10% annually (2026, based on historical data and market trends)

Focus on Internationalization: Dermapharm Holding SE is increasingly focusing on internationalizing its products to tap into new markets and expand existing market shares. This includes both the European and non-European markets.

Product Diversification: The company plans to further diversify its product portfolio, especially in the fields of dermatology and allergology. New product developments and expanding existing product lines are in focus.

Acquisitions and Partnerships: Dermapharm is pursuing an active acquisition strategy to accelerate growth through targeted purchases of companies and brands. Partnerships with other pharmaceutical companies and research institutions are also intended to strengthen innovation capabilities.

Sustainability and Digitalization: Investments in sustainable production methods and digitalization of processes are also part of the growth strategy. This is intended not only to increase efficiency but also to reduce the company's ecological footprint.

These strategic initiatives are intended to help Dermapharm solidify its market position and ensure long-term profitable growth.

Main raw materials: Pharmaceutical active ingredients, packaging materials, excipients

Countries of origin: China, India, Germany, Switzerland

Dermapharm Holding SE imports a variety of raw materials necessary for the production of its pharmaceutical products. The most important materials include pharmaceutical active ingredients, which are often sourced from countries such as China and India. These countries are known for their extensive production of generic active ingredients and offer cost-effective alternatives.

In addition, the company sources packaging materials and excipients, which are imported from both domestic sources, such as Germany, and Switzerland. These materials are essential for quality assurance and compliance with regulatory standards in production.

Diversifying the supply chains and selecting suppliers from different countries help Dermapharm minimize risks and ensure supply security.

Market share in Germany: 4.5% (2025)
Research and development ratio: 7.2% of revenue (2025)
EBITDA margin: 29.8% (2025)

Dermapharm Holding SE has established itself as a significant player in the German pharmaceutical market. With a market share of 4.5% in 2025, the company demonstrates a strong presence, particularly in the area of off-patent drugs and dietary supplements.

A key competitive advantage of Dermapharm lies in its high EBITDA margin of 29.8%, indicating an efficient cost structure and strong pricing. This margin is significantly higher compared to many competitors in the industry.

Furthermore, Dermapharm invests 7.2% of its revenue in research and development, highlighting the company's innovation capabilities. These investments enable Dermapharm to continuously introduce new products to the market and expand its product range, contributing to a stronger market position.

Overall, Dermapharm benefits from a combination of strong market presence, high profitability, and continuous innovation, providing the company with a sustainable competitive advantage.

Institutional Investor Share: 45% (2026, estimated)

Insider Purchases: No significant purchases in the last year

Insider Sales: 2.5 million euros (2026)

The institutional investor share in Dermapharm Holding SE is estimated to be 45%. This indicates a solid interest from institutional investors, suggesting confidence in the company's long-term performance.

In 2026, there were no significant insider purchases, which could indicate that insiders view the current price level as fair. However, insider sales amounting to 2.5 million euros were made, possibly due to profit-taking or personal financial decisions by the insiders.

Market share of Dermapharm Holding SE: 3.2% (estimated, 2026)

Top competitors and their market shares:

1. Bayer AG: 12.5%
2. Merck KGaA: 10.8%
3. Stada Arzneimittel AG: 9.4%
4. Teva Pharmaceutical Industries Ltd.: 8.7%
5. Sanofi: 7.9%
6. Dermapharm Holding SE: 3.2%
7. Hexal AG: 2.5%
8. Ratiopharm GmbH: 2.3%
9. Sandoz (Novartis): 2.0%
10. Pfizer Inc.: 1.8%

Moat of Dermapharm Holding SE:

Dermapharm Holding SE has a moderate moat, mainly characterized by its specialization in niche products and a strong presence in the area of off-patent pharmaceuticals. This specialization allows the company to differentiate itself from the competition in certain segments. Additionally, Dermapharm benefits from an efficient production chain and a flexible distribution structure that enables it to quickly adapt to market changes.

Compared to larger competitors like Bayer or Merck, which have extensive research and development resources as well as a global brand presence, Dermapharm's moat is less pronounced. These companies often have stronger protection through patents and a broader product range, giving them a competitive advantage.

In summary, Dermapharm has a certain advantage in specialized niches, but its moat is limited compared to major pharmaceutical companies. The competition has stronger financial resources and a larger global reach, which tends to provide them with a better moat.

Revenue Growth: 8.5% (2025) EBITDA Margin: 28.2% (2025) R&D Expenditure Growth: 12% (2025)

Dermapharm Holding SE achieved solid revenue growth of 8.5% in 2025, attributed to strong demand for its products and successful market expansion. The EBITDA margin of 28.2% indicates that the company operates efficiently and maintains strong profitability.

Another positive aspect is the growth in research and development expenditures by 12%, suggesting that Dermapharm is investing in the development of new products and focusing on innovation. This could lead to a stronger market position and additional revenue sources in the long term.

Overall, the financial performance and strategic direction of the company suggest that Dermapharm Holding SE could be a promising investment, especially for investors interested in long-term growth.

Dividend yield: 2.8% (2026, estimated)
Dividend history: Continuous payout for several years

Dermapharm Holding SE has been paying a consistent dividend in recent years, indicating a reliable dividend policy. The estimated dividend yield for 2026 is around 2.8%, which can be considered stable compared to other companies in the industry.

The company has regularly increased its dividends in the past, indicating a solid financial foundation and a sustainable business model. Analysts expect Dermapharm to continue to be able to pay an attractive dividend in the coming years, supported by continuous revenue and profit growth.